Vaccine trial aims to stop lung cancer before it starts

NCT ID NCT07169617

Summary

This study is testing a vaccine designed to prevent lung cancer in people at high risk, primarily former and current heavy smokers. The vaccine works by training the body's immune system to recognize and attack cells that could become cancerous. Researchers will enroll 80 participants to see if the vaccine is safe and successfully triggers a protective immune response.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Northwestern University

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Rocky Mountain Regional VA Medical Center

    Aurora, Colorado, 80045, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Tennessee - Knoxville

    Knoxville, Tennessee, 37920, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.